Project Grant R21NS135213
- This $2,307,536 federal Project Grant, awarded by the National Institute on Aging (CFDA 93.866 - Aging Research), will leverage a natural experiment to examine the effects of integrated palliative care on health service outcomes and disparities in Parkinson's disease and Lewy body dementia. The primary awardee, The Trustees of the University of Pennsylvania, will: Examine patterns of palliative domain care and disparities across U.S. Parkinson's specialty centers; and Test the effects of a...
- Federal Project Grant Award Summary Brigham and Women's Hospital Inc. received a $557,883 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded May 1, 2026, with a completion date of April 30, 2031. The award funds research investigating the pathogenic mechanisms of leucine-rich repeat kinase 2 (LRRK2) mutations, which are linked to familial...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $2.23 million to the University of Nevada, Las Vegas under its Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program on August 15, 2025. The project, with a completion date of July 31, 2029, addresses the underrepresentation of sexual and gender minorities (SGM)—including individuals who identify as lesbian, gay, bisexual, transgender,...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $1.81 million Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded May 11, 2026, with a completion date of April 30, 2029. The grant supports research investigating LRRK2 (Leucine-Rich Repeat Kinase 2) signaling and its role in the progression of...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $627,103 to the Research Foundation for Mental Hygiene, Inc. (operating through the New York State Psychiatric Institute) on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This five-year Project Grant, with completion scheduled for May 31, 2031, supports fundamental neuroscience research investigating the role of...
- This Project Grant, awarded June 1, 2026, by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), provides $126,789 in federal funding to The Research Foundation for the State University of New York, operating as Stony Brook University, for basic neuroscience research through December 31, 2029. The award supports fundamental investigation into the role of myocyte...
- Federal Project Grant Award Summary The National Institute on Aging (CFDA 93.866 – Aging Research) awarded a $3.4M Project Grant to Columbia University's Health Sciences Division on March 1, 2026, for a four-year initiative addressing health disparities in mild cognitive impairment (MCI) and early-stage dementia (ED) detection among Black older adults. The project, titled "Tackling Disparity with Sound: Audio-Recorded Patient-Clinician Communication for Early Detection of Mild Cognitive...
- Grant Award Summary Mayo Clinic Jacksonville received a $1.875 million Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded May 20, 2026, with completion targeted for April 30, 2029. The research project investigates enhanced PINK1 kinase activity as a therapeutic strategy against alpha-synuclein pathology and neurodegeneration in Parkinson's...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $513,109 Project Grant to the University of Pennsylvania (awarded July 15, 2026; completion date April 30, 2031) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds the development of novel statistical methodologies designed to optimize individualized treatment regimens for Parkinson's Disease by simultaneously...
- Federal Project Grant Award Summary Brigham and Women's Hospital Inc. received a $492,250 Project Grant award, effective August 1, 2026 through July 31, 2028, from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The research project, titled "Identification of the Palmitoyltransferase for Glucocerebrosidase Trafficking Receptor LIMP2 and Restoration of GBA1...
RACIAL AND ETHNIC DIFFERENCES OF NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE - ABSTRACT PARKINSON'S DISEASE (PD) IS A PROGRESSIVE AND CHRONIC NEURODEGENERATIVE BRAIN DISORDER THAT AFFECTS APPROXIMATELY 1 MILLION PEOPLE IN THE UNITED STATES. PARKINSON'S DISEASE AFFECTS ALL RACIAL AND ETHNIC POPULATIONS; HOWEVER, MEMBERS OF ETHNIC AND RACIAL MINORITIES HAVE BEEN HISTORICALLY UNDERREPRESENTED IN PD RESEARCH. THIS UNDERREPRESENTATION HAS BIASED BASIC UNDERSTANDINGS OF A DISEASE THAT IS ALREADY KNOWN TO BE HIGHLY HETEROGENEOUS IN TERMS OF CLINICAL PRESENTATION AND SYMPTOM PROGRESSION. IN PARTICULAR, NON-MOTOR SYMPTOMS EXPERIENCED BY PEOPLE LIVING WITH PD ARE MARKEDLY DIFFERENT BETWEEN INDIVIDUALS, AND NOT WELL UNDERSTOOD IN MINORITY POPULATIONS. THESE DISPARITIES ARE CONSEQUENTIAL BECAUSE TIMELY TREATMENT OF NON-MOTOR SYMPTOMS CAN IMPROVE QUALITY OF LIFE AND DELAY DISABILITY. THEREFORE, IT IS IMPERATIVE THAT THE PD COMMUNITY BROADEN ITS INCLUSIVITY BY BETTER UNDERSTANDING RACE- AND ETHNICITY-RELATED DISPARITIES OF NON-MOTOR SYMPTOMS IN PD. OUR OBJECTIVE IS TO INVESTIGATE HOW RACE AND ETHNICITY INFLUENCE THE OCCURRENCE (AIM 1), TREATMENT (AIM 2), AND BURDEN (AIM 3) OF NON-MOTOR SYMPTOMS AMONG BLACK/AFRICAN AMERICAN AND LATINO VERSUS WHITE NON- LATINO PEOPLE LIVING WITH PD. WE WILL USE DATA FROM THE FOX INSIGHT STUDY AND THE TRINETX PLATFORM TO ADDRESS OUR RESEARCH OBJECTIVES. THE FOX INSIGHT STUDY IS A GROUNDBREAKING, DECENTRALIZED, ONLINE STUDY THAT HAS SUCCESSFULLY ENROLLED AND FOLLOWED HUNDREDS OF PEOPLE WITH PD WHO ARE BLACK/AFRICAN AMERICAN OR OF LATINO ETHNICITY OR ORIGIN, AND THOUSANDS OF WHITE NON-LATINO PEOPLE LIVING WITH PD. THE TRINETX PLATFORM IS A FEDERATED NETWORK OF > 50 HEALTHCARE ORGANIZATIONS SHARING ELECTRONIC HEALTH RECORDS DATA, AND INCLUDES THOUSANDS OF PATIENTS LIVING WITH PD WHO ARE OF BLACK/AFRICAN AMERICAN RACE AND LATINO ETHNICITY. IN AIM 1, THESE DATA WILL BE USED TO COMPARE THE OCCURRENCE OF NON-MOTOR SYMPTOMS BETWEEN HISTORICALLY UNDERREPRESENTED RACIAL AND ETHNIC (BLACK/AFRICAN AMERICAN, LATINO) POPULATIONS VERSUS MORE FREQUENTLY STUDIED (WHITE NON-LATINO) POPULATIONS AMONG PEOPLE LIVING WITH PD (AIM 1). NEXT, AIM 2 WILL COMPARE FREQUENCIES OF PHARMACOLOGIC TREATMENT USE FOR NON-MOTOR SYMPTOMS BETWEEN HISTORICALLY UNDERREPRESENTED RACIAL AND ETHNIC (BLACK/AFRICAN AMERICAN, LATINO) POPULATIONS VERSUS MORE FREQUENTLY STUDIED (WHITE NON- LATINO) POPULATIONS AMONG PEOPLE LIVING WITH PD. FINALLY, AIM 3 WILL COMPARE THE MOST BOTHERSOME SYMPTOMS BETWEEN HISTORICALLY UNDERREPRESENTED RACIAL AND ETHNIC (BLACK/AFRICAN AMERICAN, LATINO) POPULATIONS VERSUS MORE FREQUENTLY STUDIED (WHITE NON-LATINO) POPULATIONS AMONG PEOPLE LIVING WITH PD. AT THE CONCLUSION OF THIS RESEARCH PROJECT, THE GOAL IS TO HAVE REDUCED SOME OF THE DISPARITIES THAT EXIST AROUND THE CURRENT KNOWLEDGE OF PD HETEROGENEITY IN UNDERREPRESENTED POPULATIONS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 5/22/26 | ||
| Not listed | $423.5k | 6/15/24 |